Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I)
Refine
Has Fulltext
- yes (31)
Is part of the Bibliography
- yes (31) (remove)
Document Type
- Journal article (31)
Language
- English (31)
Keywords
- inflammation (7)
- cytokines (5)
- inflammatory bowel disease (3)
- intestinal epithelial barrier (3)
- sepsis (3)
- Aspergillus (2)
- Caco2 cells (2)
- Crohn's disease (2)
- Ureaplasma parvum (2)
- adaptive immunity (2)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (31)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (6)
- Medizinische Klinik und Poliklinik I (6)
- Medizinische Klinik und Poliklinik II (6)
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Frauenklinik und Poliklinik (4)
- Kinderklinik und Poliklinik (4)
- Klinik und Poliklinik für Nuklearmedizin (3)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Anatomie und Zellbiologie (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 101042738 (1)
Background
The management of rectal cancer (RC) has substantially changed over the last decades with the implementation of neoadjuvant chemoradiotherapy, adjuvant therapy and improved surgery such as total mesorectal excision (TME). It remains unclear in which way these approaches overall influenced the rate of local recurrence and overall survival.
Methods
Clinical, histological and survival data of 658 out of 662 consecutive patients with RC were analyzed for treatment and prognostic factors from a prospectively expanded single-institutional database. Findings were then stratified according to time of diagnosis in patient groups treated between 1993 and 2001 and 2002 and 2010.
Results
The study population included 658 consecutive patients with rectal cancer between 1993 and 2010. Follow up data was available for 99.6% of all 662 treated patients. During the time period between 2002 and 2010 significantly more patients underwent neoadjuvant chemoradiotherapy (17.6% vs. 60%) and adjuvant chemotherapy (37.9% vs. 58.4%). Also, the rate of reported TME during surgery increased. The rate of local or distant metastasis decreased over time, and tumor related 5-year survival increased significantly with from 60% to 79%.
Conclusion
In our study population, the implementation of treatment changes over the last decade improved the patient’s outcome significantly. Improvements were most evident for UICC stage III rectal cancer.